This is the product ABT acquired from Evalve six months ago for $300 plus milestones (#msg-41374735). It is already approved in the EU and a PMA application is pending at the FDA.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.